NCT03790072View on ClinicalTrials.gov

Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL

OmnImmune®

infusion of OmnImmune® (expanded gamma delta T lymphocytes)

Trial Locations (1)

128 20

UHKT (Ustav hematologie a krevni transfuze), Prague

Sponsors

Lead Sponsor

All Listed Sponsors

lead

TC Biopharm

INDUSTRY

NCT03790072 - Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML) | Biotech Hunter | Biotech Hunter